“The next big one that comes to the market is adalimumab,” says [Napp Pharmaceutical Group Ltd.]’s director of market access and external affairs Andrew Roberts, when discussing the uptake of monoclonal antibody (MAb) biosimilars in the UK. Currently the biosimilar with the widest distribution in the UK is infliximab, with around 600,000 units distributed a year.
“The NHS policy of savings on medicines has been in place for almost a decade so manufacturers were frustrated that...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

